摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-quinazolinol, 4-[[5-chloro-2-[[(1,3-dioxolan-2-ylmethyl)methylamino]methyl]phenyl]amino]-7-methoxy- | 807640-60-4

中文名称
——
中文别名
——
英文名称
6-quinazolinol, 4-[[5-chloro-2-[[(1,3-dioxolan-2-ylmethyl)methylamino]methyl]phenyl]amino]-7-methoxy-
英文别名
4-[5-Chloro-2-[[1,3-dioxolan-2-ylmethyl(methyl)amino]methyl]anilino]-7-methoxyquinazolin-6-ol
6-quinazolinol, 4-[[5-chloro-2-[[(1,3-dioxolan-2-ylmethyl)methylamino]methyl]phenyl]amino]-7-methoxy-化学式
CAS
807640-60-4
化学式
C21H23ClN4O4
mdl
——
分子量
430.891
InChiKey
RBEQJLNZAFKULD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    30
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    89
  • 氢给体数:
    2
  • 氢受体数:
    8

反应信息

  • 作为反应物:
    描述:
    6-quinazolinol, 4-[[5-chloro-2-[[(1,3-dioxolan-2-ylmethyl)methylamino]methyl]phenyl]amino]-7-methoxy-盐酸caesium carbonate 作用下, 以 1,4-二氧六环 、 DMF (N,N-dimethyl-formamide) 为溶剂, 反应 29.0h, 生成 4,6-ethanediylidene-8H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine,18-chloro-9,10,11,12,13,14,15,20-octahydro-21-methoxy-14-methyl-
    参考文献:
    名称:
    [EN] MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS
    [FR] DERIVES DE QUINAZOLINE MACROCYCLIQUE UTILISES COMME AGENTS ANTIPROLIFERATIFS
    摘要:
    本发明涉及公式(I)的化合物,其N-氧化物形式,药用可接受的加合物盐及其立体化异构形式,其中Z代表O、CH2、NH或S;特别是Z代表NH;Y代表-C3-9烷基,-C3-9烯基,-C3-9炔基,-C3-7烷基-CO-NH-(可选择地被氨基,单或双(C1-4烷基)氨基或C1-4烷氧羰氨基取代),-C3-7烯基-CO-NH-(可选择地被氨基,单或双(C1-4烷基)氨基或C1-4烷氧羰氨基取代),C1-5烷氧基-C1-5烷基,-C1-5烷基-NR13-,-C1-5烷基,-C1-5烷基-NR14-CO-C1-5烷基,-C1-5烷基-CO NR15-C1-5烷基,-C1-6烷基-CO-NH-,-C1-6烷基-NH-CO-,-C1-3烷基-NH-CS-Het20-,-C1-3烷基-NH-CO-Het20-,-C1-2烷基-CO-Het21-CO-,-Het22-CH2-CO-NH-C1-3烷基-,-CO-NH-C1-6烷基-,-NH-CO-C1-6烷基-,-CO-C1-7烷基-,-C1-7烷基-CO-,-C1-6烷基-CO-C1-6烷基-,-C1-2烷基-NH-CO-CR16R17-NH-,-C1-2烷基-CO-NH-CR18R19-CO-,-C1-2烷基-CO-NR20-C1-3烷基-CO-,C1-2烷基-NR21-CH2-CO-NH-C1-3烷基-,或-NR22-CO-C1-3烷基-NH-;X1代表直接键,O或-O-C1-2烷基-,CO,-CO-C1-2烷基-,NR11,-NR11-C1-2烷基-,CH2-,-O-N=CH-或-C1-2烷基-;X2代表直接键,O,-O-C1-2烷基-,CO,-CO-C1-2烷基-,NR12,-NR12-C1-2烷基-,-CH2-,-O-N=CH-或-C1-2烷基-。本发明化合物的生长抑制效应和抗肿瘤活性已在体外实验中,在EGFR受体酪氨酸激酶的酶促活性测定中得到证明。
    公开号:
    WO2004105765A1
  • 作为产物:
    描述:
    6-乙酰氧基-4-氯-7-甲氧基喹唑啉 在 甲醇 作用下, 以 乙腈 为溶剂, 反应 5.0h, 生成 6-quinazolinol, 4-[[5-chloro-2-[[(1,3-dioxolan-2-ylmethyl)methylamino]methyl]phenyl]amino]-7-methoxy-
    参考文献:
    名称:
    [EN] MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS
    [FR] DERIVES DE QUINAZOLINE MACROCYCLIQUE UTILISES COMME AGENTS ANTIPROLIFERATIFS
    摘要:
    本发明涉及公式(I)的化合物,其N-氧化物形式,药用可接受的加合物盐及其立体化异构形式,其中Z代表O、CH2、NH或S;特别是Z代表NH;Y代表-C3-9烷基,-C3-9烯基,-C3-9炔基,-C3-7烷基-CO-NH-(可选择地被氨基,单或双(C1-4烷基)氨基或C1-4烷氧羰氨基取代),-C3-7烯基-CO-NH-(可选择地被氨基,单或双(C1-4烷基)氨基或C1-4烷氧羰氨基取代),C1-5烷氧基-C1-5烷基,-C1-5烷基-NR13-,-C1-5烷基,-C1-5烷基-NR14-CO-C1-5烷基,-C1-5烷基-CO NR15-C1-5烷基,-C1-6烷基-CO-NH-,-C1-6烷基-NH-CO-,-C1-3烷基-NH-CS-Het20-,-C1-3烷基-NH-CO-Het20-,-C1-2烷基-CO-Het21-CO-,-Het22-CH2-CO-NH-C1-3烷基-,-CO-NH-C1-6烷基-,-NH-CO-C1-6烷基-,-CO-C1-7烷基-,-C1-7烷基-CO-,-C1-6烷基-CO-C1-6烷基-,-C1-2烷基-NH-CO-CR16R17-NH-,-C1-2烷基-CO-NH-CR18R19-CO-,-C1-2烷基-CO-NR20-C1-3烷基-CO-,C1-2烷基-NR21-CH2-CO-NH-C1-3烷基-,或-NR22-CO-C1-3烷基-NH-;X1代表直接键,O或-O-C1-2烷基-,CO,-CO-C1-2烷基-,NR11,-NR11-C1-2烷基-,CH2-,-O-N=CH-或-C1-2烷基-;X2代表直接键,O,-O-C1-2烷基-,CO,-CO-C1-2烷基-,NR12,-NR12-C1-2烷基-,-CH2-,-O-N=CH-或-C1-2烷基-。本发明化合物的生长抑制效应和抗肿瘤活性已在体外实验中,在EGFR受体酪氨酸激酶的酶促活性测定中得到证明。
    公开号:
    WO2004105765A1
点击查看最新优质反应信息

文献信息

  • Quinazoline derivatives
    申请人:Freyne Eddy Jean Edgard
    公开号:US20100105668A1
    公开(公告)日:2010-04-29
    The present invention concerns the compounds of formula wherein Z represents NH; Y represents —C 3-9 alkyl-, —C 2-9 alkenyl-, —C 3-7 alkyl-CO—NH optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino-, —C 3-7 alkenyl-CO—NH— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino- or C 1-4 alkyloxycarbonylamino-, C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-5 alkyl-NR 14 —CO—C 1-5 alkyl-, —C 1-6 alkyl-CO—NH—, —C 1-5 alkyl-CO NR 15 —C 1-5 alkyl-, —C 1-3 alkyl-NH—CO-Het 20 -, —C 1-2 alkyl-CO-Het 21 -CO—, —C 1-2 alkyl-NH—CO—CR 16 R 17 —NH—, —C 1-2 alkyl-CO—NH—CR 18 R 19 —CO—, —C 1-2 alkyl-CO—NR 20 —C 1-3 alkyl-CO—, or —NR 22 —CO—C 1-3 alkyl-NH—; X 1 represents a direct bond, O or —O—C 1-2 alkyl-; X 2 represents a direct bond, —CO—C 1-2 alkyl-, NR 12 , —NR 12 —C 1-2 alkyl-, —O—N═CH— or —C 1-2 alkyl-; R 1 and R 2 are hydrogen or halo; R 3 are hydrogen; R 4 represents hydrogen or C 1-4 alkyloxy; R 12 and R 13 are hydrogen or C 1-4 alkyl; R 14 and R 15 are hydrogen; R 16 and R 17 each independently represent hydrogen or C 1-4 alkyl; R 18 and R 19 are hydrogen or C 1-4 alkyl optionally substituted with phenyl or hydroxy; R 20 and R 21 are hydrogen or C 1-4 alkyl optionally substituted with C 1-4 alkyloxy; Het 20 , Het 21 and Het 22 are a heterocycle selected from the group consisting pyrrolidinyl, 2-pyrrolidinonyl or piperidinyl optionally substituted with hydroxy.
  • QUINAZOLINE DERIVATIVES
    申请人:Janssen Pharmaceutica N.V.
    公开号:US20130178624A1
    公开(公告)日:2013-07-11
    The present invention concerns the compounds of formula wherein Z represents NH; Y represents —C 3-9 alkyl-, —C 2-9 alkenyl-, —C 3-7 alkyl-CO—NH optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino-, —C 3-7 alkenyl-CO—NH— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino- or C 1-4 alkyloxycarbonylamino-, C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-5 alkyl-NR 14 —CO—C 1-5 alkyl-, —C 1-6 alkyl-CO—NH—, —C 1-5 alkyl-CO NR 15 —C 1-5 alkyl-, —C 1-3 alkyl-NH—CO-Het 20 -, —C 1-2 alkyl-CO-Het 21 -CO—, —C 1-2 alkyl-NH—CO—CR 16 R 17 —NH—, —C 1-2 alkyl-CO—NH—CR 18 R 19 —CO—, —C 1-2 alkyl-CO—NR 20 —C 1-3 alkyl-CO—, or —NR 22 —CO—C 1-3 alkyl-NH—; X 1 represents a direct bond, O or —O—C 1-2 alkyl-; X 2 represents a direct bond, —CO—C 1-2 alkyl-, NR 12 , —NR 12 —C 1-2 alkyl, —O—N═CH— or —C 1-2 alkyl-; R 1 and R 2 are hydrogen or halo; R 3 are hydrogen; R 4 represents hydrogen or C 1-4 alkyloxy; R 12 and R 13 are hydrogen or C 1-4 alkyl; R 14 and R 15 are hydrogen; R 16 and R 17 each independently represent hydrogen or C 1-4 alkyl; R 18 and R 19 are hydrogen or C 1-4 alkyl optionally substituted with phenyl or hydroxy; R 20 and R 21 are hydrogen or C 1-4 alkyl optionally substituted with C 1-4 alkyloxy; Het 20 , Het 21 and Het 22 are a heterocycle selected from the group consisting pyrrolidinyl, 2-pyrrolidinonyl or piperidinyl optionally substituted with hydroxy.
  • US7648975B2
    申请人:——
    公开号:US7648975B2
    公开(公告)日:2010-01-19
  • US8394786B2
    申请人:——
    公开号:US8394786B2
    公开(公告)日:2013-03-12
  • US9273013B2
    申请人:——
    公开号:US9273013B2
    公开(公告)日:2016-03-01
查看更多